Table 1.
Demographic characteristics of 4446 patients with limited-disease small-cell lung cancer who received definite concurrent chemoradiotherapy
| Variables | LD stage (n = 4446) |
|---|---|
| Age, years | 64 ± 8.28 |
| < 65 | 2187 (49.2) |
| ≥65 | 2259 (50.8) |
| Sex (male/female) | 3797 (85.4)/649 (14.6) |
| Comorbidities | |
| HBP | 2361 (39.3) |
| DM | 1334 (22.2) |
| Hypercholesterolemia | 2314 (38.5) |
| First-line therapy | |
| Combination CRT | |
| Etoposide/platinum | 4187 (94.2) |
| Irinotecan/platinum | 259 (5.8) |
| Second-line therapy | |
| Combination therapy | |
| Etoposide/platinum | 151 (8.7) |
| Irinotecan/platinum | 774 (44.5) |
| Single-agent therapy | |
| Etoposide | 1 (0.1) |
| Irinotecan | 232 (13.3) |
| Belotecan | 342 (19.6) |
| Topotecan | 240 (13.8) |
Values are presented as mean ± standard deviation or number (%)
LD, limited disease; HBP, hypertension; DM, diabetes mellitus; CRT, chemoradiotherapy